NLRC4 and hemophagocytic syndrome: Other laboratory features of MAS, such as decreased platelet counts and fibrinogen levels are more pronounced in patients treated with tocilizumab.[12] Barsalou et al[13] recently reported effective treatment of HLH in neonates with NLRC4 functional mutations by combining anakinra and rapamycin.